Literature DB >> 3335031

Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study.

W R Shapiro1, R M Voorhies, E M Hiesiger, P B Sher, G A Basler, L E Lipschutz.   

Abstract

Using quantitative autoradiography, we investigated the entry over 90 min of [14C]methotrexate (MTX) into C6 gliomas implanted bilaterally into Wistar rat brains. The [14C]MTX was administered into the right carotid artery, yielding ipsilateral "arterial" brain and tumor concentrations and contralateral "systemic" concentrations. In a separate group of tumor-bearing rats, mannitol 1.6 M was given into the right carotid artery prior to administering the [14C]MTX to disrupt the blood-brain barrier on the ipsilateral side. [14C]MTX tissue concentrations were measured in regions of 50 x 50 x 20 microns in tumor, peritumoral brain tissue (brain adjacent to tumor), and cerebral cortex. In the nonmannitol experiments, tissue concentrations from the rats at each time interval were fitted using a nonlinear curve fitting program, and the pharmacokinetic values of influx and efflux of [14C]MTX into the three compartments were calculated. The influx rate constant K1 for [14C]MTX ranged from 1.3 to 8.2 microliters/g/min in the tumor. Influx rate constants in the cortex were 1.3-1.9 microliters/g/min and in the brain adjacent to tumor were 1.7-2.8 microliters/g/min. The efflux rate constant k2 was approximated for each tissue but was less reliable than the K1 values. The k2 for tumor, brain adjacent to tumor, and cortex was always higher than the corresponding K1. Peak [14C]MTX concentrations in the tumor were highest after arterial infusion with hyperosmolar barrier disruption, lower after arterial administration without barrier modification, and lowest after systemic administration. However, cortical [14C]MTX concentration was also highest after arterial administration with barrier modification and higher than the highest tumor concentration. Furthermore, tissue exposure (concentration x time) was also highest in the cortex after barrier disruption. The [14C]MTX concentration x time (micrograms/min/g x 90 min +/- SEM) ratio between tumor and cortex after systemic administration was 33.4 +/- 4.1:15.7 +/- 1.9; after arterial administration it was 96.3 +/- 11.7:30.3 +/- 3.1; after arterial administration with barrier disruption it was 266.6 +/- 28.8:311.2 +/- 15.9. The greatest tumor:cortex ratio (3.1:1) occurred with arterial drug administration without barrier disruption. Disrupting the barrier enough to permit increased tumor exposure actually increased cortical exposure to a greater degree. The resulting poorer therapeutic ratio would not appear to support this technique in humans, at least for neurotoxic drugs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335031

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Evaluation of systemically administered radiolabeled epidermal growth factor as a brain tumor targeting agent.

Authors:  W Yang; R F Barth; R Leveille; D M Adams; M Ciesielski; R A Fenstermaker; J Capala
Journal:  J Neurooncol       Date:  2001-10       Impact factor: 4.130

2.  Boron neutron capture therapy of brain tumors: functional and neuropathologic effects of blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine.

Authors:  W Yang; R F Barth; J H Rotaru; C P Boesel; D A Wilkie; J C Bresnahan; M Hadjiconstantinou; V M Goettl; D D Joel; M M Nawrocky
Journal:  J Neurooncol       Date:  2000-07       Impact factor: 4.130

3.  Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries.

Authors:  Bernhard Erdlenbruch; Mehrnaz Alipour; Gert Fricker; David S Miller; Wilfried Kugler; Hansjörg Eibl; Max Lakomek
Journal:  Br J Pharmacol       Date:  2003-11-03       Impact factor: 8.739

Review 4.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Influence of C6 and CNS1 brain tumors on methotrexate pharmacokinetics in plasma and brain tissue.

Authors:  Sylvain F Dukic; Matthieu L Kaltenbach; Tony Heurtaux; Guillaume Hoizey; Aude Lallemand; Richard Vistelle
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

6.  The use of intracerebral microdialysis for the determination of pharmacokinetic profiles of anticancer drugs in tumor-bearing rat brain.

Authors:  E C de Lange; J D de Vries; C Zurcher; M Danhof; A G de Boer; D D Breimer
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

7.  Leukotriene E4 selectively increase the delivery of methotrexate to the C6 gliomas in rats.

Authors:  C C Chio; S J Lin; M T Lin
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

8.  Results of a randomized trial comparing intra-arterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group trial 8420A.

Authors:  E M Hiesiger; S B Green; W R Shapiro; P C Burger; R G Selker; M S Mahaley; J Ransohoff; J C VanGilder; J Mealey; J T Robertson
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

9.  The use of intracerebral microdialysis to determine changes in blood-brain barrier transport characteristics.

Authors:  E C de Lange; M B Hesselink; M Danhof; A G de Boer; D D Breimer
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

10.  cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer. I. Distribution within the central nervous system after intravenous and intracarotid infusion.

Authors:  H Nakagawa; T Fujita; S Izumoto; S Kubo; Y Nakajima; K Tsuruzono; K Kodama; M Higashiyama; O Doi; T Hayakawa
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.